IP Library › Granted Patent US 12,427,130
Granted Patent B2
US 12,427,130 · App. 18/141,834 · Granted Sep 30, 2025

Modulators of Sestrin-GATOR2 interaction and uses thereof

Inventors: Eddine Saiah (Brookline, MA); George Vlasuk (Concord, MA)
Assignee: Navitor Pharmaceuticals, Inc.
A61K31/198A61K31/145A61K31/69A61P25/24A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,130
App. No.
18/141,834
Granted
Sep 30, 2025
Kind
B2
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Claims (20)

1. A method of reducing a depression scale score in a patient in need thereof, said method comprising administering to said patient a compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof:

2. The method of claim 1 , wherein said method further comprises administering to said patient an additional therapeutic agent or therapy.

3. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score.

4. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within fewer than six weeks of said administration of the compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

5. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within fewer than four weeks of said administration of the compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

6. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within two weeks of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

7. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within fewer than two weeks of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

8. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within one week of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

9. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within six days of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

10. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within five days of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

11. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within four days of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

12. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within three days of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

13. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within two days of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

14. The method of claim 1 , wherein said patient experiences at least a 50% reduction in depression scale score within one day of said administration of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

15. The method of claim 1 , wherein said depression scale score is the Montgomery-Asberg Depression Rating Scale (MADRS).

16. The method of claim 1 , wherein said depression scale score is the Hamilton Depression Rating Scale (HAMD-6).

17. The method of claim 1 , wherein said depression scale score is selected from the Inventory of Depression Symptomatology Self-Rated Scale (IDS-SR) and the Clinical Global Impression Severity Scale (CGI-S).

18. The method of claim 1 , wherein said patient experiences a reduction in depression scale score comparable to a reduction in depression scale score resulting from the administration of ketamine to the patient.

19. The method of claim 1 , wherein said reduction in depression scale score results from a single oral administration.

20. The method of claim 1 , wherein said reduction in depression scale score results from a plurality of oral administrations.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2026
From: NAVITOR PHARMACEUTICALS, INC.
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 075552/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2023
From: SAIAH, EDDINE; VLASUK, GEORGE
To: NAVITOR PHARMACEUTICALS, INC.
Reel/Frame 065115/0635 →
Continuity (4)
Continuation 17106584 · Nov 30, 2020
Continuation 15962123 · Apr 25, 2018
Provisional Application 62490280 · Apr 26, 2017
Related Publication 20240091184A1 · Mar 21, 2024
References Cited (288)
US 4110368A · Floyd, Jr. et al. · 1978 [cited by applicant]
US 4346110A · Palfreyman et al. · 1982 [cited by applicant]
US 4775692A · Ohno et al. · 1988 [cited by applicant]
US 5639600A · McGrath et al. · 1997 [cited by applicant]
US 6329546B1 · Shiono · 2001 [cited by applicant]
US 6458781B1 · Connor et al. · 2002 [cited by applicant]
US 6613934B1 · Jegelka et al. · 2003 [cited by applicant]
US 6689850B2 · Morini et al. · 2004 [cited by applicant]
US 6787664B2 · Anderson et al. · 2004 [cited by applicant]
US 7087648B1 · McGrath · 2006 [cited by applicant]
US 7390799B2 · Bruncko et al. · 2008 [cited by applicant]
US 8084456B2 · Burns et al. · 2011 [cited by applicant]
US 8138347B2 · Knight et al. · 2012 [cited by applicant]
US 8193228B2 · Chen et al. · 2012 [cited by applicant]
US 8431608B2 · Christos et al. · 2013 [cited by applicant]
US 8563549B2 · Burger et al. · 2013 [cited by applicant]
US 8828987B2 · Borriello et al. · 2014 [cited by applicant]
US 8895585B2 · Fujiwara et al. · 2014 [cited by applicant]
US 9315525B2 · Gazic Smilovic et al. · 2016 [cited by applicant]
US 9434760B2 · Li et al. · 2016 [cited by applicant]
US 9579284B2 · Zale et al. · 2017 [cited by applicant]
US 10053422B2 · Pourgholami et al. · 2018 [cited by applicant]
US 10100066B2 · Fetalvero et al. · 2018 [cited by applicant]
US 10414782B2 · Fetalvero et al. · 2019 [cited by applicant]
US 10653652B2 · During · 2020 [cited by applicant]
US 10752644B2 · Fetalvero et al. · 2020 [cited by applicant]
US 10912750B2 · Saiah et al. · 2021 [cited by applicant]
US 11325924B2 · Fetalvero et al. · 2022 [cited by applicant]
US 11345654B2 · Lenzini · 2022 [cited by applicant]
US 11354654B2 · Higashide et al. · 2022 [cited by applicant]
US 11679090B2 · Saiah et al. · 2023 [cited by applicant]
US 11697633B2 · Lenzini · 2023 [cited by applicant]
US 11723890B2 · Leventer et al. · 2023 [cited by applicant]
US 20030203900A1 · Quibell · 2003 [cited by applicant]
US 20040110982A1 · Anderson et al. · 2004 [cited by applicant]
US 20060264358A1 · Nussbaum et al. · 2006 [cited by applicant]
US 20070082894A1 · Burns et al. · 2007 [cited by applicant]
US 20070212428A1 · Wittlin · 2007 [cited by applicant]
US 20100022598A1 · Chen et al. · 2010 [cited by applicant]
US 20100093706A1 · Hauske · 2010 [cited by applicant]
US 20100240663A1 · Christos et al. · 2010 [cited by applicant]
US 20110288091A1 · Gray et al. · 2011 [cited by applicant]
US 20120219596A1 · Limbach et al. · 2012 [cited by applicant]
US 20120225859A1 · Burger et al. · 2012 [cited by applicant]
US 20120231993A1 · Gazic Smilovic et al. · 2012 [cited by applicant]
US 20130116430A1 · Fujiwara et al. · 2013 [cited by applicant]
US 20130261100A1 · Borriello et al. · 2013 [cited by applicant]
US 20130296245A1 · Li et al. · 2013 [cited by applicant]
US 20140186453A1 · Zale et al. · 2014 [cited by applicant]
US 20150105386A1 · Mack et al. · 2015 [cited by applicant]
US 20160137606A1 · Bissantz et al. · 2016 [cited by applicant]
US 20170114080A1 · Fetalvero et al. · 2017 [cited by applicant]
US 20170369435A1 · Pourgholami et al. · 2017 [cited by applicant]
US 20180333381A1 · Saiah et al. · 2018 [cited by applicant]
US 20190048029A1 · Fetalvero et al. · 2019 [cited by applicant]
US 20190240174A1 · During · 2019 [cited by applicant]
US 20200079800A1 · Fetalvero et al. · 2020 [cited by applicant]
US 20200131114A1 · Lenzini · 2020 [cited by applicant]
US 20210016835A1 · Moss et al. · 2021 [cited by applicant]
US 20210047347A1 · Fetalvero et al. · 2021 [cited by applicant]
US 20210169835A1 · Leventer et al. · 2021 [cited by applicant]
US 20210228523A1 · Saiah et al. · 2021 [cited by applicant]
US 20220340604A1 · Fetalvero et al. · 2022 [cited by applicant]
US 20220371985A1 · Lenzini · 2022 [cited by applicant]
US 20240018091A1 · Lenzini · 2024 [cited by applicant]
US 20240041811A1 · Leventer et al. · 2024 [cited by applicant]
DE 19623142A1 · 1997 [cited by applicant]
EP 215413A2 · 1987 [cited by applicant]
EP 0372816A1 · 1990 [cited by applicant]
EP 1389617A1 · 2004 [cited by applicant]
EP 2154139A1 · 2010 [cited by applicant]
EP 3615019 · 2021 [cited by applicant]
JP 04048212B · 1992 [cited by applicant]
JP 2002226838A · 2002 [cited by applicant]
WO WO1998008853A1 · 1998 [cited by applicant]
WO WO2000026259A1 · 2000 [cited by applicant]
WO WO200076958A2 · 2000 [cited by applicant]
WO 2003063794A3 · 2003 [cited by applicant]
WO WO2003063794A2 · 2003 [cited by applicant]
WO WO2004019973A1 · 2004 [cited by applicant]
WO WO2004089925A1 · 2004 [cited by applicant]
WO WO2004106328A1 · 2004 [cited by applicant]
WO WO2005007623A2 · 2005 [cited by applicant]
WO WO2005113554A2 · 2005 [cited by applicant]
WO WO2006078846A1 · 2006 [cited by applicant]
WO WO2006117696A2 · 2006 [cited by applicant]
WO WO2006122806A2 · 2006 [cited by applicant]
WO WO2007016176A2 · 2007 [cited by applicant]
WO WO2007044729A2 · 2007 [cited by applicant]
WO WO2007053452A1 · 2007 [cited by applicant]
WO WO2007070514A1 · 2007 [cited by applicant]
WO WO2007084786A1 · 2007 [cited by applicant]
WO WO2007129161A2 · 2007 [cited by applicant]
WO 2008038092A2 · 2008 [cited by applicant]
WO WO2008039218A2 · 2008 [cited by applicant]
WO WO2008044691A1 · 2008 [cited by applicant]
WO WO2008109943A1 · 2008 [cited by applicant]
WO WO2008118802A1 · 2008 [cited by applicant]
WO WO2009114512A1 · 2009 [cited by applicant]
WO WO2011092128A1 · 2011 [cited by applicant]
WO WO2011102964A1 · 2011 [cited by applicant]
WO 2012113847A1 · 2012 [cited by applicant]
WO 2013052393A1 · 2013 [cited by applicant]
WO 2013064703A2 · 2013 [cited by applicant]
WO WO2013142229A1 · 2013 [cited by applicant]
WO WO2014127052A1 · 2014 [cited by applicant]
WO 2014145852A2 · 2014 [cited by applicant]
WO WO2014201111A1 · 2014 [cited by applicant]
WO 2016040824A2 · 2016 [cited by applicant]
WO WO2017070518A1 · 2017 [cited by applicant]
WO WO2017083823A1 · 2017 [cited by applicant]
WO 2017185010A1 · 2017 [cited by applicant]
WO WO2018200625A1 · 2018 [cited by applicant]
WO WO2020086816A1 · 2020 [cited by applicant]
WO 2021087432A1 · 2021 [cited by applicant]
Andrzejewska et al., “Cystinosin is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex Controlling Mammalian Target of Rapamycin Complex 1 Signaling,” J Am Soc Nephrol. 2016;27(6):1678-88. [cited by applicant]
Bar-Peled and Sabatini, “Regulation of mTORC1 by amino acids,” Trends Cell Biol. 2014;24(7):400-6. [cited by applicant]
Bar-Peled et al., “A Tumor suppressor complex with GAP activity for the RAG GTPases that signal amino acid sufficiency to mTORC1,” Science. 2013;340(6136):1100-6. [cited by applicant]
Bar-Peled et al., “Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1,” Cell. Sep. 14, 2012;150(6):1196-208. [cited by applicant]
Berge et al., “Pharmaceutical salts,” J Pharm Sci. 1977;66(1):1-19. [cited by applicant]
Bidinosti et al., “CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency,” Science. Mar. 11, 2016;351(6278):1199-203. [cited by applicant]
Bowling et al., “Antipsychotics Activate mTORC1-Dependent Translation to Enhance Neuronal Morphological Complexity,” Sci Signal. Jan. 14, 2014;7(308):ra4. [cited by applicant]
Brenner et al., “Synthesis and CD Spectr in MeCN, MeOH, and H [cited by applicant]
Brugarolas et al., “Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex,” Genes Dev. Dec. 1, 2004;18(23):2893-904. [cited by applicant]
Buckbinder et al., “Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes,” Proc Natl Acad Sci U S A. Oct. 25, 1994; 91(22):10640-4. [cited by applicant]
Budanov and Karin, “The p53 target genes sestrinl and sestrin2 connect genotoxic stress and mTOR signaling,” Cell. Aug. 8, 2008;134(3):451-60. [cited by applicant]
Buerger et al., “Localization of Rheb to the endomembrane is critical for its signaling function,” Biochem Biophys Res Commun. Jun. 9, 2006;344(3):869-80. [cited by applicant]
Bull et al., “Conjugate additions of organocuprates to a 3-methylene-6-isopropyldiketopiperazine acceptor for the asymmetric synthesis of homochiral a-amino acids,” J Chem Soc Perkin 1. 2001;3281-7. [cited by applicant]
Bures et al., “Chiral imidazole derivatives synthesis from enantiopure N-protected a-amino acids,” Tetrahedron Asymmetry. Jan. 2005;16(7):1347-54. [cited by applicant]
Cao et al., “Autophagy Is Disrupted in a Knock-in Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis,” J Biol Chem. Jul. 21, 2006;281(29):20483-93. [cited by applicant]
Cao et al., “Translational control of entrainment and synchrony of the suprachiasmatic circadian clock by mTOR/4E-BP1 signaling,” Neuron. Aug. 21, 2013;79(4):712-24. [cited by applicant]
CAS STN Abstract RN 1779709-85-1, entered Jun. 14, 2015. [cited by applicant]
CAS STN Abstract, RN 1378266-29-5 (Pub. Jun. 14, 2012). [cited by applicant]
Cas STN Abstract, RN 1555441-22-9 (Pub. Feb. 25, 2014). [cited by applicant]
CAS STN Abstract, RN 1698493-03-6 (Pub. May 5, 2015). [cited by applicant]
CAS STN Abstract, RN 1780718-09-3 (Pub. Jun. 15, 2015). [cited by applicant]
Chantranupong et al., “The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1,” Cell Rep. Oct. 9, 2014;9(1):1-8. [cited by applicant]
Chauhan et al., “Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG),” Neurosci Res. Sep.-Oct. 2013;77(1-2):102-9. [cited by applicant]
Chen et al., “Design, Synthesis, Activity, and Structure of a Novel Class of Matrix Metalloproteinase Inhibitors containing a Heterocyclic P2-P3 Amide Bond Isotere,” Bioorg Med Chem Lett. 1996;6(13):1601-6. [cited by applicant]
Chi, “Regulation and function of mTOR signaling in T cell fate decisions,” Nat Rev Immunol. Apr. 20, 2012;12(5):325-38. [cited by applicant]
Child et al., “Cardiac mTORC1 Dysregulation Impacts Stress Adaptation and Survival in Huntington's Disease,” Cell Rep. Apr. 24, 2018;23(4):1020-1033. [cited by applicant]
Ching et al., “mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy,” Hum Mol Genet. Mar. 15, 2013;22(6):1167-79. [cited by applicant]
Cuthbertson et al., “Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle,” FASEB J. Mar. 2005;19(3):422-4. [cited by applicant]
Deboves et al., “A new route to hydrophobic amino acids using copper-promoted reactions of serine-derived organozinc reagents,” J Chem Soc Perkin 1. 2000;4284-92. [cited by applicant]
Delgoffe et al., “The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment,” Immunity. Jun. 19, 2009;30(6):832-44. [cited by applicant]
Di Polo, “Dendrite pathology and neurodegeneration: focus on mTOR,” Neural Regen Res. Apr. 2015;10(4):559-61. [cited by applicant]
Dibble et al., “TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1m,” Mol Cell. Aug. 24, 2012;47(4):535-46. [cited by applicant]
Efeyan et al., “Amino acids and mTORC1: from lysosomes to disease,” Trends Mol Med. Sep. 2012;18(9):524-33. [cited by applicant]
Fossale et al., “Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis,” BMC Neurosci. Dec. 10, 2004;5:57. [cited by applicant]
Garami et al., “Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2,” Mol Cell. Jun. 2003;11(6):1457-66. [cited by applicant]
Gordon et al., “Regulation of muscle protein synthesis and the effects of catabolic states,” Int J Biochem Cell Biol. Oct. 2013;45(10):2147-57. [cited by applicant]
Gurpur et al., “Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy,” Am J Pathol. Mar. 2009;174(3):999-1008. [cited by applicant]
Ham et al., “Leucine as a treatment for muscle wasting: A critical review,” Clin Nutr. Dec. 2014;33(6):937-45. [cited by applicant]
Hirose et al., “RagA is a functional homologue of S. cerevisiae Gtr1p involved in the Ran/Gsp1- GTPase pathway,” J Cell Sci. Jan. 1998;111 ( Pt 1):11-21. [cited by applicant]
Howell et al., “A growing role for mTOR in promoting anabolic metabolism,” Biochem Soc Trans. Aug. 2013;41(4):906-12. [cited by applicant]
Ignácio et al., “New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs,” Br J Clin Pharmacol. Nov. 27, 2015;82(5):1280-1290. [cited by applicant]
Inoki et al., “Rheb GTPase is a direct target of TSC2 Gap activity and regulates mTOR signaling,” Genes Dev. Aug. 1, 2003;17(15):1829-34. [cited by applicant]
Ito et al., “A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals,” Cancer Sci. Jan. 2003;94(1):3-8. [cited by applicant]
Ivanova et al., “Altered mTOR signalling in nephropathic cystinosis,”J Inherit Metab Dis. May 2016;39(3):457-464. [cited by applicant]
Jung et al., “Synthesis of 3-Substituted and 3, 4-Disubstituted Pyrazolin-5-Ones,” Tetrahedron, 2002, vol. 58, pp. 3639-3646. [cited by applicant]
Kang et al., “mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin,” Science. Jul. 26, 2013;341(6144):1236566. [cited by applicant]
Katholnig et al., “Immune responses of macrophages and dendritic cells regulated by mTOR signaling,” Biochem Soc Trans. Aug. 2013;41(4):927-33. [cited by applicant]
Kim and Guan, “mTOR: a pharmacologic target for autophagy regulation,” J Clin Invest. Jan. 2015;125(1):25-32. [cited by applicant]
Kim et al., “Nutrient regulation of the mTOR complex 1 signaling pathway,” Mol. Cells. 2013;35(6):463-73. [cited by applicant]
Kim et al., “Regulation of TORC1 by Rag GTPases in nutrient response,” Nat Cell Biol. Aug. 2008;10(8):935-45. [cited by applicant]
Koot et al., “Synthesis of Statine From (S)-Malic Acid; Stereocontrol Via Radical Cyclization,” Tetrahedron Letters, 1991, vol. 32, No. 3, pp. 401-404. [cited by applicant]
Kye et al., “SMN regulates axonal local translation via miR-183/mTOR pathway,” Hum Mol Genet. Dec. 1, 2014;23(23):6318-31. [cited by applicant]
Köhler et al., “Inflammation in Depression and the Potential for Anti-Inflammatory Treatment,” Curr Neuropharmacol. 2016;14(7):732-42. [cited by applicant]
Lambe et al., “Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice,” Neuron. Sep. 25, 2003;40(1):139-50. [cited by applicant]
Laplante and Sabatini, “mTOR signaling in growth control and disease,” Cell. Apr. 13, 2012;149(2):274-93. [cited by applicant]
Lee et al., “Functional effects of a pathogenic mutation in Cereblon (CRBN) on the regulation of protein synthesis via the AMPK-mTOR cascade,” J Biol Chem. Aug. 22, 2014;289(34):23343-52. [cited by applicant]
Lee et al., “Platelets support extracellular sialylation by supplying the sugar donor substrate,” J Biol Chem. Mar. 28, 2014;289(13):8742-8. [cited by applicant]
Lee et al., “Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes,” Neuron. Jan. 21, 2015;85(2):303-15. [cited by applicant]
Leger et al., “Atrogin-1, MuRF1 and FoXO, as Well as Phosphorylated GSK-3beta and 4E-BP1 Are Reduced in Skeletal Muscle of Chronic Spinal Cord-Injured Patients,” Muscle Nerve, vol. 40, No. 1, Jul. 2009, pp. 69-78. [cited by applicant]
Lehnert, “Knoevenagel-Kondensation Mit TiCI4/Base-V, 3-Alkyliden-und-3-Aryliden-2,4-Pentandione aus Aldehyden und Acetylaceton,” Synthesis. 1974:667-669. [cited by applicant]
Li et al., “Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure,” Biol Psychiatry. Apr. 15, 2011;69(8):754-61. [cited by applicant]
Li et al., “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists,” Science. Aug. 20, 2010;329(5994):959-64. [cited by applicant]
Liebau et al., “Dysregulated autophagy contributes to podocyte damage in Fabry's disease,” PLoS One. May 1, 20137;8(5): e63506. [cited by applicant]
Lin et al., “Activation of mTOR Ameliorates Fragile X Premutation rCGG Repeat-Mediated Neurodegeneration,” PLoS One. Apr. 23, 2013;8(4):e62572. [cited by applicant]
Liu et al., “GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine,” Neuropsychopharmacology. May 2017;42(6):1231-1242. [cited by applicant]
Liu et al., “Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions,” J Neurosci. Nov. 1, 2002;22(21):9453-64. [cited by applicant]
Long et al., “Rheb binds and regulates the mTOR kinase,” Curr Biol. Apr. 26, 2005;15(8):702-13. [cited by applicant]
Love, “Demyelinating diseases,” J Clin Pathol. Nov. 2006;59(11):1151-9. [cited by applicant]
Léger et al., “Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients,” Muscle Nerve. Jul. 2009;40(1):69-78. [cited by applicant]
Macovei et al., “Polyclonal antibodies: a cheap and efficient tool for screening of enantioselective catalysts,” Chem Commun. May 11, 2012;48(37):4411-13. [cited by applicant]
Malkesman et al., “The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents,” Biol Psychiatry. May 1, 2010;67(9):864-71. [cited by applicant]
Manzi and Wasko, “Inflammation-mediated rheumatic diseases and atherosclerosis,” Ann Rheum Dis. May 2000;59(5):321-5. [cited by applicant]
McVey et al., “CHO cells knocked out for TSC2 display an improved productivity of antibodies under fed batch conditions,” Biotechnol Bioeng. Sep. 2016;113(9):1942-52. [cited by applicant]
Nagamori et al., “Structure-Activity Relations of Leucine Derivatives Reveal Critical Moieties for Cellular Uptake and Activation of mTORC1-Mediated Signaling,” Amino Acids, 2016, vol. 48, No. 4, pp. 1045-1048. [cited by applicant]
Nakamura et al., “Role of the mTOR complex 1 pathway in the in vivo maintenance of the intestinal mucosa by oral intake of amino acids,” Geriatr Gerontol Int. Jan. 2012;12(1):131-9. [cited by applicant]
Napolitano et al., “Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis,” EMBO Mol Med. Feb. 2015;7(2):158-74. [cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 219681321, AKOS024124980, Source: AKos Consulting & Solutions. https://pubchem.ncbi.nlm.nih.gov/substance/219681321. Accessed Nov. 22, 2016. [cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 4757389, SID 4757389, Source: ChemDB. https://pubchem.ncbi.nlm.nih.gov/substance/4757389. Accessed Feb. 16, 2017. [cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 8685219, SID 8685219, Source: DiscoveryGate. https://pubchem.ncbi.nlm.nih.gov/substance/8685219. Accessed Nov. 22, 2016. [cited by applicant]
Nelson et al., “Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice,” Acta Neuropathol Commun. Feb. 14, 2014;2(20). [cited by applicant]
Nobukuni et al., “Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase,” Proc Natl Acad Sci U S A. Oct. 4, 2005;102(40):14238-43. [cited by applicant]
Norrmén et al., “mTORC1 controls PNS myelination along the mTORC1-RXR-SREBP-lipid biosynthesis axis in Schwann cells,” Cell Rep. Oct. 23, 2014;9(2):646-60. [cited by applicant]
Novarino et al., “Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy,” Science. Oct. 19, 2012;338(6105):394-7. [cited by applicant]
O'Brien et al., “Regulation of T-cell survival and mitochondrial homeostasis by TSC1,” Eur J Immunol. Nov. 2011;41(11):3361-70. [cited by applicant]
Ojima et al., “New Synthesis of Nitrogen Heterocycles Through Amide-Directed Hydrocarbonylation . . . ,” J. Org. Chem., 1991, vol. 56, pp. 2024-2030. [cited by applicant]
Panchaud et al., “Amino Acid Deprivation Inhibits TORC1 Through a GTPase-Activating Protein Complex for the Rag Family GTPase Gtr1,” Sci Signal. May 28, 2013;6(277):ra42. [cited by applicant]
Park et al., “TSC1 regulates the balance between effector and regulatory T cells,” J Clin Invest. Dec. 2013;123(12):5165-78. [cited by applicant]
Pasiakos et al., “Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis,” Am J Clin Nutr. Sep. 2011;94(3):809-18. [cited by applicant]
Payne et al., “L-Leucine improves the anemia and developmental defects associates with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway,” Blood. Sep. 13, 2012;120(11):2214-24. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2018/029288, dated Jun. 14, 2018. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2019/057815, dated Jan. 6, 2020. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2020/058475, dated Feb. 1, 2021. [cited by applicant]
Pearce et al., “Action of BTN1, the yeast orthologue of the gene mutated in Batten disease,” Nat Genet. May 1999;22(1):55-8. [cited by applicant]
Pedroso et al., “Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, energy Balance, and Glucose Homeostasis,” Nutrients. May 22, 2015;7(5):3914-37. [cited by applicant]
Peeters et al., “PA26 is a candidate gene for heterotaxia in humans: identification of a novel PA26-related gene family in human and mouse,” Hum Genet. May 2003;112(5-6):573-80. [cited by applicant]
Pelà et al., “Racemic synthesis and solid phase peptide synthesis application of the chimeric valine/leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid,” Pharmazie. 2014;69(7):496-9. [cited by applicant]
Peng et al., “Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling,” Cell. Sep. 25, 2014;159(1):122-133. [cited by applicant]
Pollizzi et al., “mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation,” J Clin Invest. May 2015;125(5):2090-108. [cited by applicant]
Punzo et al., “Stimulation of the insulin/, TOR pathway delays cone death in a mouse model of retinitis pigmentosa,” Nat Neurosci. Jan. 2009;12(1):44-52. [cited by applicant]
Rennie, “Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover,” Appl Physiol Nutr Metab. Jun. 2009;34(3):377-81. [cited by applicant]
Roccio et al., “Regulation of the small GTPase Rheb by amino acids,” Oncogene. Feb. 2, 2006;25(5):657-64. [cited by applicant]
Saito et al., “Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin,” J Biochem. Mar. 2005;137(3):423-30. [cited by applicant]
Sancak et al., “Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids,” Cell. Apr. 16, 2010;141(2):290-303. [cited by applicant]
Sancak et al., “The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1,” Science. Jun. 13, 2008;320(5882):1496-501. [cited by applicant]
Saucedo et al., “Rheb promotes cell growth as a component of the insulin/TOR signalling network,” Nat Cell Biol. Jun. 2003;5(6):566-71. [cited by applicant]
Schürmann et al., “Cloning of a Novel Family of Mammalian GTP-binding Proteins (RagA, RagBs, RagB1) with Remote Similarity to the Ras-related GTPases,” J Biol Chem. Dec. 1, 1995;270(48):28982-8. [cited by applicant]
Sekiguchi et al., “Novel G Proteins, Rag C and Rag D, Interact with GTP-binding Proteins, Rag A and Rag B,” J Biol Chem. Mar. 9, 2001;276(10):7246-57. [cited by applicant]
Smith et al., “The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses,” J Biol Chem. May 13, 2005;280(19):18717-27. [cited by applicant]
Song et al., “A simple method for preparation of N-mono- and N,N-di-alkylated a-amino acids,” Tetrahedron Lett. 2000;41:8225-30. [cited by applicant]
Song et al., “mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy,” Am J Physiol Cell Physiol. Dec. 2010;299(6):C1256-66. [cited by applicant]
Stein et al., “Protein kinetics during and after long-duration spaceflight on MIR,” Am J Physiol. Jun. 1999;276(6 Pt 1):E1014-21. [cited by applicant]
Stocker et al., “Rheb is an essential regulator of S6K in controlling cell growth in [cited by applicant]
Takikita et al., “Pertubed myelination process of premyelinating oligodendrocyte in Niemann-Pick type C mouse,” J Neuropathol Exp Neurol. Jun. 2004;63(6):660-73. [cited by applicant]
Tarlungeanu et al., “Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder,” Cell. Dec. 1, 2016;167(6):1481-1494.e18. [cited by applicant]
Tee et al., “Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling,” Proc Natl Acad Sci U S A. Oct. 15, 2002;99(21):13571-6. [cited by applicant]
Tsun et al., “The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1,” Mol Cell. Nov. 21, 2013;52(4):495-505. [cited by applicant]
Tyler et al., “Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation,” J Neurosci. May 13, 2009;29(19):6367-78. [cited by applicant]
Vergarajauregui et al., “Autophagic dysfunction in mucolipidosis type IV patients,” Hum Mol Genet. Sep. 1, 2008;17(17):2723-37. [cited by applicant]
Visualization Bioactivity: (3r, 5S)-3-Hydroxy-5-isobutyl-pyrrolidin-2-one, Jan. 1, 2001, pp. 1-2, XP093022482. [cited by applicant]
Visualization Bioactivity: 5-isobutyl-1, 2-dihydro-pyrazol-3-one, Jan. 1, 1901, pp. 1-4, XP093022481. [cited by applicant]
Wang et al., “Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1,” Science. Jan. 9, 2015;347(6218):188-94. [cited by applicant]
Wang et al., “The amino acid transporter SLC38A9 is a key component of a lysosomal membrane complex that signals arginine sufficiency to mTORC1,” Science, vol. 347, No. 6218, Jan. 2015 (pp. 188-194). [cited by applicant]
Wang et al., “Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells,” Proc Natl Acad Sci U S A. Nov. 26, 2013;110(50):E4894-903. [cited by applicant]
Warner-Schmidt and Duman, “VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants,” Proc Natl Acad Sci U S A. Mar. 13, 2007;104(11):4647-52. [cited by applicant]
Wolfson et al., “Sestrin2 is a leucine sensor for the mTORC1 pathway,” Science. Jan. 1, 2016;351(6268):43-8. [cited by applicant]
Wong et al., “ [cited by applicant]
Xu et al., “A Mental Retardation-linked Nonsense Mutation in Cereblon Is Rescued by Proteasome Inhibition,” J Biol Chem. Oct. 11, 2013;288(41):29573-85. [cited by applicant]
Xu et al., “Improved transcription and translation with L-leucine stimulation of mTORC1 in Roberts syndrome,” BMC Genomics. 2016;17(25). [cited by applicant]
Yang et al., “Reduced Excitatory Neurotransmission and Mild Autism-Relevant Phenotypes in Adolescent Shank3 Null Mutant Mice,” J Neurosci. May 9, 2012;32(19):6525-41. [cited by applicant]
Yang et al., “The tumor suppressor Tscl enforces quiescence of naive T cells to promote immune homeostasis and function,” Nat Immunol. Jul. 17, 2011;12(9):888-97. [cited by applicant]
Ye et al., “Chemical aminoacylation of tRNAs with fluorinated amino acids for in vitro protein mutagenesis,” Beilstein J Org Chem. Apr. 20, 2010;6(40). [cited by applicant]
Zoncu et al., “mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase,” Science. Nov. 4, 2011;334(6056):678-83. [cited by applicant]
Abe et al., “Mammalian target of Rapa,ycin (mTOR) Activation Increases Axonal Growth Capacity of Injured Peripheral Nerves,” J Biol Chem. 2010;285(36):28034-43. [cited by applicant]
Ali et al., “IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells,” Front Immunol. 2015;6:355. [cited by applicant]
Caira, M. R., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, 1998, vol. 198, pp. 163-208; Springer Verlag, Berlin, Heidelberg.https://doi.org/10.1007/3-540-69178-2_5, first available onlin… [cited by applicant]
Database PubChem [online], PubChem CID 12425333, Feb. 8, 2007. [cited by applicant]
Database PubChem [online], PubChem CID 12425335, Feb. 8, 2007. [cited by applicant]
Database PubChem [online], PubChem CID 71334221, May 21, 2013. [cited by applicant]
Database PubChem [online], PubChem CID 45082328, Mar. 30, 2010. [cited by applicant]
Database PubChem [online], PubChem CID 10607912, Oct. 25, 2006. [cited by applicant]
Database PubChem [online], PubChem CID 22329417, Dec. 5, 2007. [cited by applicant]
Database PubChem [online], PubChem CID 117532356, Feb. 15, 2016. [cited by applicant]
Database PubChem [online], PubChem CID 76590157, Aug. 3, 2014. [cited by applicant]
Database PubChem [online], PubChem CID 57677193, Aug. 19, 2012. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2016/058188 dated Mar. 17, 2017. [cited by applicant]
Navitor Pharmaceuticals, Inc. (Sponsor): Anonymous, “Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression,” Jul. 10, 2018, XP093089717, … [cited by applicant]
Braga, D., “Crystal Polymorphism and Multiple Crystal Forms,” Struct. Bond, 2009, vol. 132, pp. 25-50. [cited by applicant]
Hilfker, R., “Relevance of Solid-State Properties for Pharmaceutical Products,” Polymorphism in the Pharmaceutical Industry, 2006, pp. 1-19. [cited by applicant]
Chemical Abstract Registry No. 1892397-17-9, indexed in the Registry File on STN CAS Online Apr. 18, 2016. [cited by applicant]
Chemical Abstract Registry No. 1865561-59-6, indexed in the Registry File on STN CAS Online Feb. 12, 2016. [cited by applicant]
Chemical Abstract Registry No. 1864740-65-7, indexed in the Registry File on STN CAS Online Feb. 11, 2016. [cited by applicant]
Navitor's Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression Sep. 12, 2019. [cited by applicant]
Taro Kato et al., “Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation”, Journal of Clinical Investigation, 129/6, pp. 2542-2554, May 20, 2019. [cited by applicant]
Threlfall, “Analysis of Organic Polymoprhs a Review,” Analyst, Oct. 1995, vol. 120, pp. 2435-2460. [cited by applicant]
Byrn, “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, USA, Kluwer Academic Publishers, Jul. 1, 1995, vol. 12, No. 7, pp. 945-954. [cited by applicant]
Oshima, “Crystallization of Polymorphs and Pseudo-Polymorphs and its Control,” Pharm Stage, 2007, vol. 6, No. 10, pp. 48-53. [cited by applicant]
Chen, Q. et al., “Indium-Mediated Diastereoselective Allylation of D- and L-Glyceraldimines With 4-Bromo-1,1,1-Trifluoro-2-Butene: Highly Stereoselective Synthesis . . . ,” Journal of Organic Chemistry, vol. 71, No. 10,… [cited by applicant]
Andrés et al., “Diastereoselective Synthesis of Beta-Amino-Alpha-(trifluoromethyl) Alcohols from Homochiral Alpha-Dibenzylamino Aldehydes”, European Journal of Organic Chemistry, 2004, 2004(7):1558-1566. [cited by applicant]
Arthur et al., “In Situ Deprotection and Incorporation of Unnatural Amino Acids during Cell-Free Protein Synthesis”, Chemistry—A European Journal, 2013, 19(21):6824-6830. [cited by applicant]
Ayi et al., “Reaction of Hydrogen Fluoride in Pyridine Solution with cis-Cyano-2-and cis-Amido-2-aziridines. Preparation of Beta-fluoro-Alpha-amino Acids and Esters by Means of Acidic Hydrolysis and Alcoholysis of Beta-… [cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates “The 100 mg approach””, International Journal of Pharmaceutics, 2004, 275(1-2):1-12. [cited by applicant]
Behrends et al., “New matrix metalloproteinase inhibitors based on Gamma-fluorinated Alpha-aminocarboxylic and Alpha-aminohydroxamic acids”, Bioorganic & Medicinal Chemistry, 2015, 23(13):3809-3818. [cited by applicant]
Biava et al., “Biocatalytic synthesis of (2S)-5,5,5-trifluoroleucine and improved resolution into (2S,4S) and (2S,4R) diastereoisomers”, Tetrahedron Letters, 2013, 54(28):3662-3665. [cited by applicant]
Bilgicer et al., “A Coiled Coil with a Fluorous Core”, Journal of the American Chemical Society, 2001, 123 (19):4393-4399. [cited by applicant]
Cai, “Molecular Mechanisms of Amino Acid Regulation of mTORC1 Signaling Pathway”, Science, 2016, 47(5):385 (With English Abstract Only). [cited by applicant]
CAS Registry Nos. 1514651-80-9, 1511535-78-6, 1508824-75-6, 1504420-40-9, 1500455-72-0, 1499542-11-8, 1269152-34-2, 1251279-41-0, 1250690-21-1, 1250247-88-1, 1249515-43-2, 1248722-02-2, 1247182-68-8, 2010-2014 [Date of … [cited by applicant]
Chiu et al., “The Mood Stabilizer Lithium Potentiates the Antidepressant-Like Effects and Ameliorates Oxidative Stress Induced by Acute Ketamine in a Mouse Model of Stress”, International Journal of Neuropsychopharmacol… [cited by applicant]
Ikutani, “Studies of the N-Oxides of N,N-Dialkylamino Acids. I. The Syntheses of N,N-Dimethyl Neutral Amino Acids and Corresponding N-Oxides”, Bulletin of the Chemical Society of Japan, Jul. 1968, 41(7):1679-1681. [cited by applicant]
Meixia et al., “A New Therapeutic Target for Depression—The mTOR Signaling Pathway”, Journal of Military Surgeon in Southwest China, Jan. 2013, 15(1):53-59 (7 pages of English Translation and 3 pages of Official Copy). [cited by applicant]
Shmatova et al., “Friedel-Crafts alkylation of natural amino acid-derived pyrroles with CF3-substituted cyclic imines”, Mendeleev Communications, 2013, 23(2):92-93. [cited by applicant]
Singhal et al., “Drug polymorphism and dosage form design: a practical perspective”, Advanced Drug Delivery Reviews, 2004, 56(3):335-347. [cited by applicant]
Sorochinsky et al., “Chemical deracemization and (S) to (R) interconversion of some fluorine-containing alpha-amino acids”, Journal of Fluorine Chemistry, 2013, 152:114-118. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2023/036588, mailed on Feb. 12, 2024, 6 pages. [cited by applicant]